
Sign up to save your podcasts
Or
Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies.
Read the full article:
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00119-5?dgcid=buzzsprout_icw_podcast_generic_langas
Continue this conversation on social!
Follow us today at...
https://bsky.app/profile/lancetgastrohep.bsky.social
https://www.linkedin.com/company/langastro/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://youtube.com/thelancettv
Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies.
Read the full article:
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00119-5?dgcid=buzzsprout_icw_podcast_generic_langas
Continue this conversation on social!
Follow us today at...
https://bsky.app/profile/lancetgastrohep.bsky.social
https://www.linkedin.com/company/langastro/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://youtube.com/thelancettv
131 Listeners
7 Listeners
325 Listeners
69 Listeners
0 Listeners
496 Listeners
3,336 Listeners
90 Listeners
24 Listeners
519 Listeners
427 Listeners
23 Listeners
0 Listeners
0 Listeners
2 Listeners
1 Listeners
0 Listeners
2 Listeners
1 Listeners
0 Listeners
1 Listeners
0 Listeners
0 Listeners
1 Listeners
0 Listeners
0 Listeners
0 Listeners
0 Listeners
0 Listeners
16 Listeners
11 Listeners
0 Listeners
0 Listeners
3 Listeners